R-Biopharm AG: Flu tests from R-Biopharm also detect new virus variants
Darmstadt, November 25, 2022: The flu season has begun and different virus variants are also circulating in Germany. With the flu tests from biotechnology company R-Biopharm, patients quickly have certainty: Its RIDA®GENE Flu assays also reliably detect the two novel variants. The company made the announcement with regard to influenza A H1N1pdm09, which is circulating primarily in the United Kingdom, and the H3N2 subtype, which was rampant in Denmark in the spring and is currently dominating influenza activity in Germany.
"Mutations in the target gene (MP gene) can affect the diagnostic performance of influenza screening assays, producing false-negative test results," explains Dr. Andreas Simons, Head of Product Management at R-Biopharm. " Alignments of the detection systems we used with the described sequences of the two novel virus variants showed no mismatches. Their reliable detection is not affected by the described mutations."
This means laboratories can continue to reliably confirm or rule out influenza infections using R-Biopharm's RIDA®GENE (PG0505, PG0545, PG6825) assays. The tests are multiplex real-time RT-PCR for the direct qualitative detection of influenza viruses.
About R-Biopharm
R-Biopharm AG, located in Darmstadt, is one of Germany's leading biotechnology companies. Founded in 1988, the company is family-run in the second generation and considers itself as a pioneer for health and quality of life. Its aspiration: to provide the highest possible precision, safety, clarity and certainty in prevention, therapy and healing. To this end, R-Biopharm develops technologies, products and solutions for Clinical Diagnostics, Nutrition Care and Food and Feed Analytics – and does so in internationally recognized top quality. R-Biopharm is the world market leader for test systems in the field of allergen analysis.
R-Biopharm unites research, development and sales under one roof in order to respond to ever new challenges with agile processes and to accompany the steadily growing world population into a new health era. The company is represented in more than 120 countries – through 29 subsidiaries and 120 distributors. It employs around 1,400 people worldwide (690 at its headquarters in Darmstadt) and was repeatedly recognized with the "Sustainability Award" for sustainable and profitable growth.
Press contact:
Simone Feiler
Head of Corporate Brand Communication
https://r-biopharm.com/de/kontakt/presse
https://r-biopharm.com/de/news-presse/download-galerie
R-Biopharm AG
An der neuen Bergstraße 17
64297 Darmstadt
Phone: 0 61 51 - 81 02-538
Mobile: 0 160 - 55 273 60
Fax: 0 61 51 - 81 02-40
Email: s.feiler@r-biopharm.de
Images
About news aktuell GmbH
As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Green completes a CHF 480 million refinancing and ac-celerates its investment programs in Switzerland1.12.2022 13:31:06 CET | Pressemelding
Green is increasing its investment in Switzerland and is planning further develop-ments to help hyperscale companies and enterprises with the rising demand for secure and energy-efficient data centers.
Grunenthal Group: Janneke van der Kamp joins Grünenthal as new Chief Commercial Officer22.11.2022 11:27:30 CET | Press release
(Aachen, Germany): Grünenthal today announced that Janneke van der Kamp will join Grünenthal as the new Chief Commercial Officer (CCO), effective 1 March 2023. Janneke van der Kamp joins Grünenthal from Novartis, where she most recently served as Head of Pharma Region Europe. The Dutch native brings broad experience in the pharmaceutical industry from several roles including General Manager, Global Neurosciences Franchise Head and Global Head of Product and Portfolio Strategy for the entire Novartis Pharma portfolio. She worked closely with Research & Development and the Licensing & Acquisitions teams to strengthen the company’s pipeline. Janneke van der Kamp has vast expertise in launching and growing key brands across several disease areas. She is a studied chemist and holds an MBA from INSEAD. As CCO of Grünenthal, Janneke van der Kamp will be responsible for the entire Global Commercial Organisation and serve as a member of the Corporate Executive Board. Her focus will be to contin
The high-performance single-seater 777 hypercar is born in Monza22.11.2022 11:05:00 CET | Press release
(Monza, Italy): – The 777 hypercar is a new Italian hypercar born of the excellent partnership with Andrea Levy, Dallara, and Gibson, built from technology used in motorsports and all informations and images are on www.777hypercar.com. 777 hypercar is built by 777 Motors, the car manufacturer based in the Autodromo Nazionale Monza and founded by Andrea Levy, an entrepreneur, car collector, racing driver, and president of MIMO Milano Monza Motorshow. The 777 hypercar project will be presented on November 22, limited to just 7 units, each of which will cost 7 million euros. 777 hypercar is at the top for performance thanks to an FIA-homologated carbon monocoque developed by Dallara, which generate an incredible downforce of 2,100 kg at a speed of 370 km/h, an extremely low weight of 900 kg, and a lateral acceleration from 3.5 to 4 g that keeps the car glued to the asphalt, giving an incredible estimate lap time of just 1 minute and 33 seconds in the Monza Circuit. The engine is a natural
BMW Group secures CO2-reduced steel for global production network16.11.2022 16:17:18 CET | Pressemelding
Lower CO2 emissions for over one third of global steel purchasing
Reboots extends its partnership with Spanish national football player Pedri González15.11.2022 09:43:36 CET | Press release
(Schluechtern, Germany) – Reboots, the leading European supplier of recovery boots and pants, announces the extension of its partnership with the exceptional football talent Pedri González (19). Together on the road to success The past year has been particularly successful for Pedri. Already at the beginning of the partnership with Reboots, the professional football player reached a new milestone in his sporting career by winning the Golden Boy Award 2021 in addition to the Kopa Trophy and numerous outstanding achievements with FC Barcelona. "Reboots is keen to enter into long- term partnerships. That's why we are delighted to continue to support Pedri's career and assist his regeneration," says Tom Keller, CEO of Reboots. The partners are planning more joint projects in the coming year to raise awareness about the importance of regeneration at a young age. The past year was also a special one for Reboots. The company launched the world's smallest recovery boots device: the smart Reboo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom